ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1649

Parameters by FDG-PET/CT Are Useful for Predicting Spontaneous Regression in MTX Associated Lymphoproliferative Disorder

Tomohiro Kameda1, Shusaku Nakashima1, Hiromi Shimada1, Risa Wakiya1, Mai Fahmy Mansour1, Mikiya Kato1, Koichi Sugihara1, Rina Semba1, Mao Mizusaki1, Norimitsu Kadowaki1 and Hiroaki Dobashi2, 1Kagawa University, Takamatsu, Japan, 2Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kita-gun, Japan

Meeting: ACR Convergence 2021

Keywords: FDG-PET/CT, methotrexate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Methotrexate associated lymphoproliferative disorder (MTX-LPD) has various histological types from benign and malignant. Some MTX-LPDs spontaneously regress after discontinuation of MTX, even though they have been diagnosed with malignant lymphoma. However it is difficult to predict spontaneous regression (SR) of MTX-LPD. On the other hand, FDG-PET/CT is used for diagnosis of malignant lymphoma.

We investigate the usefulness of FDG-PET/CT for predictive factor of SR in MTX-LPD.

Methods: We enrolled 18 MTX-RA-LPD patients, which was histopathologically determined to be malignant and performed FDG-PET/CT from 2005 to 2019. We divided these cases into spontaneous regression cases (SR group; 9 cases) and cases that treated with chemotherapy after MTX discontinuation (CTx group; 9 cases), and compared the difference as follow subjects between two groups; biomarker (serum LDH and sIL-2R) at LPD onset, SUVmax to evaluate malignant tumor activity by FDG-PET/CT, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) which refer to metabolically active volume of the tumor segmented FDG-PET/CT. In addition, we analyzed cut off levels, sensitivity and specificity using statistical software JMP.

Results: The level of sIL-2R was significantly lower in SR group. In addition, MTV and TLG by FDG-PET/CT was significantly lower in SR group, although SUVmax is no difference between two groups. Cut off levels of sIL-2R, MTV and TLG were1728 U/ml (sensitivity; 77.8%, specificity; 88.9%) 103.42 ml (sensitivity; 88.9%, specificity; 88.9%) and 361.75 ml (sensitivity; 88.9%, specificity; 88.9%), respectively.

Conclusion: We suggested that serum sIL-2R, MTV and TLG were useful for predict of SR in MTX-LPD.


Disclosures: T. Kameda, None; S. Nakashima, None; H. Shimada, None; R. Wakiya, None; M. Fahmy Mansour, None; M. Kato, None; K. Sugihara, None; R. Semba, None; M. Mizusaki, None; N. Kadowaki, None; H. Dobashi, None.

To cite this abstract in AMA style:

Kameda T, Nakashima S, Shimada H, Wakiya R, Fahmy Mansour M, Kato M, Sugihara K, Semba R, Mizusaki M, Kadowaki N, Dobashi H. Parameters by FDG-PET/CT Are Useful for Predicting Spontaneous Regression in MTX Associated Lymphoproliferative Disorder [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/parameters-by-fdg-pet-ct-are-useful-for-predicting-spontaneous-regression-in-mtx-associated-lymphoproliferative-disorder/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/parameters-by-fdg-pet-ct-are-useful-for-predicting-spontaneous-regression-in-mtx-associated-lymphoproliferative-disorder/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology